http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-0111531-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02542dbae5d862aec5709db5dc5fcf9c
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-04
filingDate 2001-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4c0a82eb1a06a0289669d0749c7b515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a36b2d56126f0e5f7b72cd00ef96a7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8232adf831a387b26aefffb4182041a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_caf68df16cee70b34db11855131f59e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ba018b2250bda4f4ff7357ea38ce948
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fafa6a7c1e77dfe31ac33df375c7f17f
publicationDate 2004-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-0111531-A
titleOfInvention Pyrido [2,3-d] pyrimidine and pyrimido [4,5-d] pyrimidine nucleosides
abstract "NUCLEOSIDES OF FIRY [2,3D] PYRIMIDINE AND PIRIMIDINE [4,5-D] PYRIMIDINE". A purine nucleoside analog includes a pyrido [2,3-d] pyrimidine or a pyrimido [4,5-d] pyrimidine and additionally has a sugar moiety that is optionally modified at the C2 <39>, C3 <39> position. , C4 <39> and / or C5 <39>. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both the purine nucleoside analogs and the corresponding prodrugs are employed in reducing neoplastic cell development.
priorityDate 2000-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425172376
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID582898
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21948575
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414042117
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559203

Total number of triples: 31.